76956-02-0

76956-02-0 structure

Name: Lavoltidine
Chemical Name: loxtidine
CAS Number: 76956-02-0
Molecular Formula: C₁₉H₂₉N₅O₂
Molecular Weight: 359.46600
Catalog: Signaling Pathways GPCR/G Protein Histamine Receptor
Create Date: 2018-07-09 10:16:20
Modify Date: 2024-01-12 16:49:28
Lavoltidine (Loxtidine) is an an orally active, irreversible and highly potent histamine H2-receptor antagonist. Lavoltidine strongly inhibits gastric acid secretion and also induces hypergastrinemia[1].

Name	loxtidine
Synonyms	LAVOLTIDINE Lavoltidina Lavoltidinum [1-methyl-5-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]-1,2,4-triazol-3-yl]methanol Loxtidinum Loxtidina Loxtidine Lavoltidinum [INN-Latin] Loxtidinum [Latin] Lavoltidine [INN:BAN] Loxtidina [Spanish]

Description	Lavoltidine (Loxtidine) is an an orally active, irreversible and highly potent histamine H2-receptor antagonist. Lavoltidine strongly inhibits gastric acid secretion and also induces hypergastrinemia[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> Histamine Receptor Signaling Pathways >> GPCR/G Protein >> Histamine Receptor
Target	H2 Receptor
In Vivo	Lavoltidine (Loxtidine; 0.5 g/L; orally (drinking water); changed weekly; for 3 months) shows partial suppression of both gastric acid secretion and progression to neoplasia. Lavoltidine inhibits gastric atrophy, hyperplasia, and dysplasia in H felis-infected INS-GAS mice[1]. Lavoltidine treatment for 6 months inhibits gastric tumors in H felis-infected INS-GAS mice[1]. Animal Model: Male hypergastrinemic mice (INS-GAS mice) infected with Helicobacter felis[1] Dosage: 0.5 g/L Administration: Orally (drinking water); changed weekly; for 3 months Result: Showed partial suppression of both gastric acid secretion and progression to neoplasia.
References	[1]. Takaishi S, et al. Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.